A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal

Silva, Rufino; Gonçalves, Carla; Meireles, A.; Teixeira, Carla; Rosa, Paulo Caldeira; Monteiro-Grillo, Manuel; Canelas, Joaquim; Carneiro, Ângela; Flores, Rita

doi:10.20344/amp.8217

Cited by 4 publications

(10 citation statements)

References 14 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 6 , 8 , 9 , 12 However, this number was reported as low as 3-4 in most of the real-world practice studies. 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 In addition, 12-13 visits are necessary in an ideal PRN treatment follow-up protocol. 6 , 7 The mean visit number was 6.9 in our study.…”

Section: Discussionmentioning

confidence: 99%

“…In several previous real-world studies the mean visit number was found to be between 6 and 12. 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 …”

Section: Discussionmentioning

confidence: 99%

“…In most real-world studies, visit and injection numbers were determined to be very far from the ideal. 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 This may be secondary to heavy patient load, visit and injection scheduling problems, and patient compliance. Therefore, we might suppose that the PRN treatment regimen may not be suitable for the treatment of nAMD in daily practice according to our results and most of the other studies results.…”

Section: Discussionmentioning

confidence: 99%

“… 8 However, most of the subsequently published real-world practice studies revealed that it was not possible to obey the strict follow-up and retreatment criteria of randomized controlled trials in daily practice. 10 , 11 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 Most of these studies showed that the PRN regimen resulted in less frequent patient monitoring and injections. Several single-center and multicenter national studies were conducted to evaluate this phenomenon.…”

Section: Introductionmentioning

confidence: 99%

“…Several single-center and multicenter national studies were conducted to evaluate this phenomenon. 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 Therefore, we conducted this multicenter study to assess the real-world outcomes of intravitreal anti-VEGF treatment in nAMD patients in 9 tertiary centers, all of which are located in or near İstanbul, the most populated city in Turkey, and we believe may reflect the general trends of treatment regimens in Turkey.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Real-World Outcomes of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration in Turkey: A Multicenter Retrospective Study, Bosphorus Retina Study Group Report No: 1

Özkaya

Karabaş

Alagöz

et al. 2018

tjo

View full text Add to dashboard Cite

Objectives:To evaluate the real-world outcomes of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment in neovascular age-related macular degeneration (nAMD) patients.Materials and Methods:Multicenter, retrospective, interventional, non-comparative study. The records of nAMD patients treated with an anti-VEGF agent on a pro re nata treatment regimen basis between January 2013 and December 2015 were reviewed. The patients who completed a follow-up period of 12 months were included. Primary outcome measures of this study were the visit and injection numbers during the first year.Results:Eight hundred eighty eyes of 783 patients met the inclusion criteria for the study. Mean number of visits at month 12 was 6.9±2.5 (range: 1-15). Mean number of injections at month 12 was 4.1±1.9 (range: 1-11). Mean visual acuity at baseline and months 3, 6, and 12 was 0.90±0.63 LogMAR (range: 0.0-3.0), 0.79±0.57 LogMAR (range: 0.0-3.0), 0.76±0.57 LogMAR (range: 0.0-3.0), and 0.79±0.59 LogMAR (range: 0.0-3.0), respectively. Mean central retinal thickness at baseline and months 6 and 12 was 395±153 μm (range: 91-1582), 330±115 μm (range: 99-975), and 332±114 μm (range: 106-1191), respectively.Conclusion:The numbers of visits and injections were much lower than ideal and were insufficient with the pro re nata treatment regimen.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In several previous real-world studies the mean visit number was found to be between 6 and 12. 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 …”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Real-World Outcomes of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration in Turkey: A Multicenter Retrospective Study, Bosphorus Retina Study Group Report No: 1

Özkaya

Karabaş

Alagöz

et al. 2018

tjo

View full text Add to dashboard Cite

show abstract

Results of anti-VEGF treatment for neovascular AMD in eyes with different baseline visual acuity in Turkish population-based on real life data-Bosphorus retina study group

Öztürk

Özkaya

Karabaş

et al. 2023

Photodiagnosis and Photodynamic Therapy

View full text Add to dashboard Cite

Bimonthly, treat‐and‐extend and as‐needed ranibizumab in naïve neovascular age‐related macular degeneration patients: 12‐month outcomes of a randomized study

Gálvez

Barquet

Figueroa

et al. 2020

Acta Ophthalmologica

View full text Add to dashboard Cite

To assess the noninferiority of the treat-and-extend (T&E) and fixed bimonthly regimens of 0.5 mg intravitreal ranibizumab as compared with the pro re nata (PRN) in na€ ıve patients with neovascular age-related macular degeneration (nAMD). Methods: Phase IV, randomized, 12-month, multicentre trial. Patients aged ≥50 years with nAMD and visual impairment [best-corrected visual acuity (BCVA) between 23 and 78 Early Treatment Diabetic Retinopathy Study (ETDRS) letters] were eligible. Patients (one eye per patient) were randomized to bimonthly, n = 103, T&E, n = 99 or PRN, n = 104. Noninferiority was established at five letters ETDRS. Results: The mean (95% CI) difference in BCVA at 12 months was 7.2 (4.2-10.2), 6.4 (2.9-9.8), and 8.0 (51.1-11.0) in the bimonthly, T&E and PRN, respectively. The bimonthly or T&E regimens were not inferior to the PRN scheme. All regimens were associated with a significant reduction of central subfield thickness and volume. The mean (95% CI) number of injections in the bimonthly regimen (7.6, 7.5-7.7) was similar as compared with the PRN regimen (7.4, 6.7-8.0) (p = 0.159) but lower than in the T&E regimen (9.3, 8.9-9.7) (p < 0.001). Conclusion: At 12 months, bimonthly and T&E ranibizumab were noninferior to PRN in na€ ıve nAMD. Key words: best-corrected visual acuity-fixed bimonthly-intravitreal anti-VEGF-neovascular age-related macular degeneration-pro re nata-ranibizumab-treat-and-extend † The In-Eye Study Group members are listed in Appendix 1.

show abstract

A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal

Abstract: These findings indicate that as-needed treatment resulted in under-dosing in a real-life setting in Portugal. Such limitations may also be related to increasing numbers of patients, resulting in clinic saturation.

Cited by 4 publications

References 14 publications

Real-World Outcomes of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration in Turkey: A Multicenter Retrospective Study, Bosphorus Retina Study Group Report No: 1

Real-World Outcomes of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration in Turkey: A Multicenter Retrospective Study, Bosphorus Retina Study Group Report No: 1

Results of anti-VEGF treatment for neovascular AMD in eyes with different baseline visual acuity in Turkish population-based on real life data-Bosphorus retina study group

Bimonthly, treat‐and‐extend and as‐needed ranibizumab in naïve neovascular age‐related macular degeneration patients: 12‐month outcomes of a randomized study

Contact Info

Product

Resources

About